Suppression of myeloid cell arginase activity leads to therapeutic response in Kras mutant lung cancer by activating anti-tumor immunity

被引：0
|
作者：
Miret, Juan J. [1 ]
Kirschmeier, Paul [1 ]
Wu, Min [1 ]
Huang, Wei [1 ]
Walker, William [1 ]
Palakurti, Sangeetha [1 ]
Saccomano, Nick [2 ]
Hammerman, Peter S. [1 ]
Wong, Kwok-Kin [3 ]
Akbay, Esra [4 ]
机构：
[1] Dana Farber Canc Inst, Belfer Inst, Boston, MA 02115 USA
[2] Array Biopharma, Boulder, CO USA
[3] NYU, Div Hematol & Med Oncol, Boston, MA USA
[4] UT Southwestern Med Ctr, Dallas, TX USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-4065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4065
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
    Umelo, Ijeoma Adaku
    De Wever, Olivier
    Kronenberger, Peter
    Van Deun, Jan
    Noor, Alfiah
    Singh, Kshitiz
    Teugels, Erik
    Chen, Gang
    Bracke, Marc
    De Greve, Jacques
    ONCOTARGET, 2015, 6 (24) : 20132 - 20144
  • [32] Therapeutic targeting of TREM1 with PY159 promotes myeloid cell reprogramming and unleashes anti-tumor immunity
    Mayes, Erin
    Juric, Vladi
    Binnewies, Mikhail
    Canaday, Pamela
    Lee, Tian
    Dash, Subhadra
    Pollack, Joshua L.
    Rudolph, Joshua
    Huang, Vicky
    Du, Xiaoyan
    Jahchan, Nadine
    Ramoth, Asa J.
    Mankikar, Shilpa
    Norng, Manith
    Santamaria, Carlos
    Baker, Kevin P.
    Liang, Linda
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [33] Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer
    Si-si Wang
    Wei Liu
    Dalam Ly
    Hao Xu
    Limei Qu
    Li Zhang
    Cellular & Molecular Immunology, 2019, 16 : 6 - 18
  • [34] Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer
    Wang, Si-si
    Liu, Wei
    Ly, Dalam
    Xu, Hao
    Qu, Limei
    Zhang, Li
    CELLULAR & MOLECULAR IMMUNOLOGY, 2019, 16 (01) : 6 - 18
  • [35] Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity
    Slavin, Shimon
    Moss, Ralph W.
    Bakacs, Tibor
    PHARMACOLOGICAL RESEARCH, 2014, 79 : 9 - 12
  • [36] IL-6 contributes to the suppression of T and NK cell anti-tumor activity in EGFR-mutant NSCLC
    Patel, Sonia
    Nilsson, Monique
    Yang, Yan
    Yu, Xiaoxing
    Zhang, Fahao
    Poteete, Alissa
    Ren, Xiaoyang
    Shen, Li
    Wang, Jing
    Le, Xiuning
    Heymach, John
    CANCER RESEARCH, 2022, 82 (12)
  • [37] Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
    Yang, Yinli
    Li, Ling
    Jiang, Zhansheng
    Wang, Bin
    Pan, Zhanyu
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (12) : 2523 - 2532
  • [38] Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
    Yinli Yang
    Ling Li
    Zhansheng Jiang
    Bin Wang
    Zhanyu Pan
    Cancer Immunology, Immunotherapy, 2020, 69 : 2523 - 2532
  • [39] SOX9 drives KRAS-induced lung adenocarcinoma progression and suppresses anti-tumor immunity
    Hua Zhong
    Wen Lu
    Yong Tang
    Clotilde Wiel
    Yong Wei
    Jian Cao
    Gregory Riedlinger
    Thales Papagiannakopoulos
    Jessie Yanxiang Guo
    Martin O. Bergo
    Yibin Kang
    Shridar Ganesan
    Hatim E. Sabaawy
    Sharon R. Pine
    Oncogene, 2023, 42 : 2183 - 2194
  • [40] SOX9 drives KRAS-induced lung adenocarcinoma progression and suppresses anti-tumor immunity
    Zhong, Hua
    Lu, Wen
    Tang, Yong
    Wiel, Clotilde
    Wei, Yong
    Cao, Jian
    Riedlinger, Gregory
    Papagiannakopoulos, Thales
    Guo, Jessie Yanxiang
    Bergo, Martin O.
    Kang, Yibin
    Ganesan, Shridar
    Sabaawy, Hatim E.
    Pine, Sharon R.
    ONCOGENE, 2023, 42 (27) : 2183 - 2194
12345